Daclatasvir Nitroso
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds. Daclatasvir is used along with another medication (sofosbuvir [Solvadi]) to treat a certain type of chronic hepatitis C (an ongoing viral infection that damages the liver). Daclatasvir is in a class of antiviral medications called hepatitis C virus (HCV) NS5A inhibitors.Daclatasvir Nitroso is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Daclatasvir Nitroso CAS NO:NA chemically represented as Methyl ((S)-1-((S)-2-(5-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-[1,1'-biphenyl]-4-yl)-1-nitroso-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate. Synchemia is the leading manufacturing and exporter of Daclatasvir Nitroso . We supply Daclatasvir Nitroso with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N014631 |
| CAS No | NA |
| Mol.F. | C22H17N7O |
| Mol.Wt. | 395.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014632 |
| CAS No | NA |
| Mol.F. | C22H17N7O |
| Mol.Wt. | 395.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014633 |
| CAS No | NA |
| Mol.F. | C22H16N8O2 |
| Mol.Wt. | 424.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014634 |
| CAS No | NA |
| Mol.F. | C20H22N8O7 : Ca |
| Mol.Wt. | 486.4 : 40.1 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014635 |
| CAS No | NA |
| Mol.F. | C20H22N8O7 : Ca |
| Mol.Wt. | 486.4 : 40.1 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014636 |
| CAS No | NA |
| Mol.F. | C20H21N9O8 : Ca |
| Mol.Wt. | 515.4 : 40.1 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014637 |
| CAS No | NA |
| Mol.F. | C20H20N6O7 |
| Mol.Wt. | 456.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014638 |
| CAS No | NA |
| Mol.F. | C20H19N7O8 |
| Mol.Wt. | 485.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014639 |
| CAS No | NA |
| Mol.F. | C20H20N6O7 |
| Mol.Wt. | 456.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014640 |
| CAS No | NA |
| Mol.F. | C19H19F3N4O4 |
| Mol.Wt. | 424.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014641 |
| CAS No | NA |
| Mol.F. | C16H17N5OS |
| Mol.Wt. | 327.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014642 |
| CAS No | NA |
| Mol.F. | C9H12N2O3 |
| Mol.Wt. | 196.2 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014643 |
| CAS No | NA |
| Mol.F. | C13H13N3O2 |
| Mol.Wt. | 243.3 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014644 |
| CAS No | NA |
| Mol.F. | C17H18N4O2 |
| Mol.Wt. | 310.4 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014645 |
| CAS No | NA |
| Mol.F. | C29H29N7O7 |
| Mol.Wt. | 587.6 |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N014646 |
| CAS No | NA |
| Mol.F. | C11H16N2O4 |
| Mol.Wt. | 240.3 |
| INV STATUS | CUSTOM SYNTHESIS |